BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earnings for BioCryst Pharmaceuticals, Inc. (BCRX)
Earnings in 2023 (TTM): $-226,229,000
According to BioCryst Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-226,229,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of BioCryst Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-226,229,000 | $-226,539,000 |
| 2022 | $-244,384,000 | $-247,117,000 |
| 2021 | $-181,809,000 | $-184,062,000 |
| 2020 | $-182,814,000 | $-196,567,000 |
| 2019 | $-108,897,000 | $-120,065,000 |
| 2018 | $-101,252,000 | $-101,252,000 |
| 2017 | $-65,782,000 | $-65,782,000 |
| 2016 | $-55,144,000 | $-55,144,000 |
| 2015 | $-43,019,000 | $-43,019,000 |
| 2014 | $-45,189,000 | $-45,189,000 |
| 2013 | $-30,108,000 | $-30,108,000 |
| 2012 | $-39,081,000 | $-39,081,000 |
| 2011 | $-56,948,000 | $-56,948,000 |
| 2010 | $-33,853,183,000 | $-32,733,000 |
| 2009 | $-13,452,000 | $-13,452,000 |
| 2008 | $-24,732,000 | $-24,731,570 |
| 2007 | $-29,055,000 | $-29,055,524 |
| 2006 | $-26,098,768,000 | $-43,617,853 |
| 2005 | $-26,098,768,000 | $-26,098,768 |
| 2004 | $-21,104,121,000 | $-21,104,121 |
| 2003 | $-12,700,083,000 | $-12,700,000 |
| 2002 | $-16,928,671,000 | $-16,928,671 |
| 2001 | $-4,985,976,000 | $-4,985,976 |
| 2000 | $-11,577,842,000 | $-11,577,842 |
| 1999 | $-6,900,000 | $-5,300,000 |
| 1998 | $-4,700,000 | $-4,800,000 |
| 1997 | $-10,600,000 | $-10,600,000 |
| 1996 | $ | $-7,700,000 |
| 1995 | $-8,400,000 | $-8,600,000 |
| 1994 | $ | $-6,900,000 |